Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

For the multifaceted and complex diseases, multi-omics could define groups of patients with distinct endotypes exhibiting heterogeneous treatment responses due to their particular underlying molecular ...

State Key Laboratory of Advanced Processing and Recycling of Nonferrous Metals, Lanzhou University of Technology, Lanzhou 730050, China ...

Here, we review the mechanism(s) of action of erlotinib, as well as the results of Phase I, II and III trials with this drug in NSCLC, which have led to the worldwide approval of erlotinib ...

Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Its cis-binding mechanism is claimed to improve T reg-depletion ...

Activating agents enable the efficient preparation of organozinc complexes from zinc metal and organohalides, but their mechanisms had been obscured by the heterogeneous nature of these systems.

A joint research group team led by Sayuri Tsukahara and Tetsuji Kakutani of the University of Tokyo has clarified a mechanism of how retrotransposons, genetic elements that can "jump around ...